Noxopharm Ltd. (AU:NOX) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Noxopharm Limited has partnered with a seasoned Australian contract research organization to support its upcoming HERACLES clinical trial, focusing on areas such as drug safety and data management. This collaboration aims to ensure efficient trial execution and reliable data collection, marking a significant step forward for Noxopharm’s innovative cancer and inflammation treatments. The company is also progressing in selecting a Phase 1 unit to further advance the trial.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.